secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001485003-23-000089
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio reports Q4 net loss $7.6M; reiterates support for Carisma merger ahead of shareholder vote
--------------------------------------------------------------------------------

- Q4 net loss $7.6M ($0.04/shr) vs net income $8.9M in Q4 2021; FY net loss $19.9M ($0.10/shr).
- Cash, equivalents and marketable securities $166.9M as of Dec 31, 2022.
- Board increased special cash dividend to $75M (~$0.36/shr) under amended merger with Carisma; CVR period extended to Mar 2027.
- ISS and Glass Lewis recommend voting 'FOR' all merger proposals at Mar 2, 2023 special meeting.
- Nasdaq granted exception from $1.00 bid price requirement to complete merger by Mar 10, 2023 or face delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/0001485003-23-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000089/sesn-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer